Die Onkologie pp 1073-1093 | Cite as

Endometriumkarzinom

  • G. von Minckwitz
  • A. Pfleiderer
  • M. Kaufmann

Zusammenfassung

Das Endometriumkarzinom stellt die fünfthäufigste (nach dem Mamma-, Darm-, Bronchial- und Ovarialkarzinom) Krebserkrankung der Frau dar. In den alten Bundesländern belief sich die Neuerkrankungsrate im Jahre 1990 auf ca. 7800 Fälle, was einer Inzidenz von 24,7 pro 100000 Einwohnern pro Jahr entspricht. Die standardisierte Inzidenz lag in Europa bei 19,2 und weltweit bei 13.7. Im gleichen Zeitraum lag die Inzidenz des Zervixkarzinoms bei ca. 16,2% (Becker et al. 1991). Damit hat sich das Häufigkeitsverhältnis der beiden Karzinome in den letzten Jahrzehnten umgekehrt. Ursächlich hierfür wurde die Östrogensubstitution während des Klimakteriums angeführt, jedoch zeigte sich ein vergleichbarer Trend in Norwegen oder der Tschechoslowakei, wo eine Substitution unüblich war (Persson 1985). Somit dürfte in erster Linie die gestiegene Lebenserwartung für die beobachteten Entwicklungen verantwortlich sein.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aalders JG, Abeler V, Kolstad P, Onsrud U (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 940 patients.Obstet Gynecol 56: 419–427Google Scholar
  2. Aalders JG, Abeler V, Kolstad P (1984) Stage IV endometrial carcinoma: a clinical and histopathological study of 83 patients.Gynecol Oncol 17: 75–84Google Scholar
  3. Abeler VM, Kjörstad KE (1990) Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases. Gynecol Oncol 39: 226–271Google Scholar
  4. Aclerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A (1996) Endometrial carcinoma - relative effectiveness of adjuvant irradiation vs. therapy reserved for relapse. Gynecol Oncol 60: 177–183Google Scholar
  5. Akkerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A (1996) Endometrial carcinoma - relative effectiveness of adjuvant irradiation vs. therapy reserved for relapse. Gynecol Oncol 60: 177–183Google Scholar
  6. Assikis VJ, Bilimoria MM, Muenzner HD, Lurain JR, Jordan VC (1996) Mutations of the estrogen receptor in endometrial carcinoma:evidence of an association with high tumor grade. Gynecol Oncol 63: 192–199PubMedGoogle Scholar
  7. Atad J, Weill S, Ben-David Y, Hallak M, Klein O, Lurie M, Abramovici H (1994) Intraoperative frozen section examination of myometrial invasion depth in patients with endometrial carcinoma. In J Gynecol Cancer 4: 352–355Google Scholar
  8. Baker D (1990) Estrogen replacement therapy in patients with previous endometrial carcinoma. CompTher 16: 28–35Google Scholar
  9. Ball HG (1996) Do we know the best therapy for early endometrial cancer? Gynecol Oncol 54: 98–306Google Scholar
  10. Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium:a Gynecologic Oncology Group study.Gynecol Oncol 62: 278–81PubMedGoogle Scholar
  11. Barakat RR, Park RC, Grigsby PW, Muss HD, Norris HJ (1997) Corpus: Epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and Practise of Gynecologic Oncology, 2nd edn. Lippincott-Raven, Philadelphia, p 884Google Scholar
  12. Becker N, Frentzel-Beyme R, Wagner G (1991) Atlas of cancer mortality in the Federal Republic of Germany 1945–1990, 3rd edn. Springer, Berlin Heidelberg New York Tokyo; Update unter www.dkfz-heidelberg.de Google Scholar
  13. Behbakht K, Yordan EL, Casey C, DeGeest K, Massad LS, Kirschner CV, Wilbanks GD (1994) Prognostic indicators of survival in advanced endometrial cancer.Gynecol Oncol 55: 363–367Google Scholar
  14. Benedet JL, EhlenTG, Kovacs E, Ludwig H (1995) Corpus uteri carcinoma.ln: Hermanek P et al. (eds) Prognostic factors in cancer. UICC. Springer, Berlin Heidelberg New York Tokyo, pp 193–202Google Scholar
  15. Berchuck A, Boyd J (1995) Molecular basis of endometrial cancer. Cancer 76 [Suppl]: 2034–2040PubMedGoogle Scholar
  16. Berchuck A (1997) Endometrial carcinoma and its precursors. Curr Ther Endocrinol Metab 6: 599–602PubMedGoogle Scholar
  17. Berends MJ, Kleibeuker JH, de Vries EG, Mourits MJ, Hollema H, Pras E, van der Zee AG (1999) The importance of family history in young patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 82: 139–41PubMedGoogle Scholar
  18. Boente MP,Yordan EL, Macintosh DG, Grendys EC,Orandi YA, Davies S, Beck D,Graham JE, Miller A (1993) Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 51: 316–322Google Scholar
  19. BurkeTW, Heller PB, Woodward JE, Davidson SA, Hoskins WJ, Park RC (1990) Treatment failure in endometrial carcinoma. Obstet Gynecol 75: 96–101Google Scholar
  20. BurkeTW, Munkarah A, Kavanagh JJ, Morris M, Levenback C,Tornos C, Gershenson DM (1993) Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51: 397–400Google Scholar
  21. Calvert AH (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14: 2273–2278PubMedGoogle Scholar
  22. Carcangiu ML, Chambers JT (1992) Uterine papillary serous carcinoma: A study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma,absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47: 298–305PubMedGoogle Scholar
  23. Carey MS, O’Connell GJ,Johanson CR et al. (1995) Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 57: 138–144PubMedGoogle Scholar
  24. Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG (1996) Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 60: 409–411PubMedGoogle Scholar
  25. Childers JM, Brzechffa PR, Hatch KD, Surwit EA (1993) Laparoscopically assisted surgical staging (LASS) of endometrial cancer.Gynecol Oncol 51: 33–38Google Scholar
  26. Christopherson WM, Alberhasky RC, Connelly Pi (1982) Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study of 46 cases. Am J Clin Pathol 77: 534PubMedGoogle Scholar
  27. Coleman RL, Schinck JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR (1993) DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.Gynecol Oncol 50: 20–24Google Scholar
  28. Connelly PJ, Alberhasky RC, Christopherson WM (1982) Carcinoma of the endometrium. Ill. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 59: 569–575PubMedGoogle Scholar
  29. Corscaden JA, Gusberg SB (1947) The background of cancer of the corpus. Am J Obstet Gynec 53: 419PubMedGoogle Scholar
  30. Cosa NZ-UK Endometrial Cancer Study Groups (1996) Pelvic lymphadenectomy in high risk endometrial cancer. Int J Gynecol Cancer 6: 102–107Google Scholar
  31. Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Franssen E, Roche K (1997) A phase Il study of leuprolide in advanced/ recurrent endometrial cancer. Gynecol Oncol 64: 126–129PubMedGoogle Scholar
  32. Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw W, Clarke-Pearson DL (1985) Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151 (7): 922–932PubMedGoogle Scholar
  33. Creasman WT, Henderson D, Hinshaw W,Clarke-Pearson DL (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67: 326–330Google Scholar
  34. Creasman WT, Morrow CR Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer (a Gynecologic Oncology Group Study). Cancer 60: 2035–2041PubMedGoogle Scholar
  35. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189–2197PubMedGoogle Scholar
  36. Demopoulos RI, Genega E,Vamvakas E, Karlson E, Mittal K (1982) Papillary carcinoma of the endometrium: morphometric predictors of survival. Int J Gynecol Pathol 15: 110–118Google Scholar
  37. Deppe G (1990) Chemotherapy for endometrial cancer. In: Deppe G (ed) Chemotherapy of gynecologic cancer, 2nd edn. Wiley-Liss, New York, pp 155–174Google Scholar
  38. du Bois A, Luck HJ, Meier W et al. (1997) Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase Ill trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.Semin Oncol 24 [Suppl]: S15–44–15–52Google Scholar
  39. Dubeau I (1993) Etiology and detection of gynecologic cancer. In: Morrow CP,Curtin JP,Townsend DE (eds) Synopsis of gynecologic oncology,4th edn. Churchill Livingstone, New York, pp 1–22Google Scholar
  40. Elliott P, Green D, Coates A, Krieger M, Russell M, Coppleson M, Solomon J, Tattersall M (1994) The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer 4: 84–93PubMedGoogle Scholar
  41. Evans AT Ill, Gaffey TA, Malkasian GD Jr, Annegers JF (1980) Clinicopathologic review of 118 granulosa and 82 theca cell tumors.Obstet Gynecol 55: 231–238Google Scholar
  42. Fanning J,Tsukada Y, Piver MS (1990) Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 37: 47–50Google Scholar
  43. FIGO (1989) Announcement, FIGO stages - 1988 Revision. Gynecol Oncol 35: 125–126Google Scholar
  44. FIGO (1990) Changes in gynecologic cancer staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 162: 610–611Google Scholar
  45. Fisher B,Costantino JP,Wickerham DL et al.(1998)Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Nat! Cancer Inst 90:1371–1388Google Scholar
  46. Fishman DA, Roberts KB, Chambers JT, Kohorn El, Schwartz PE, Chambers SK (1996) Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 61: 189–196PubMedGoogle Scholar
  47. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R (1993) Pelvic lymphadenectomy in the surgical treatment of endometrial cancer.Gynecol Oncol 49: 177–180Google Scholar
  48. Goff BA, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW (1994) Surgical stage IV endometrial carcinoma:a study of 47 cases.Gynecol Oncol 52: 237–240Google Scholar
  49. Goff BA, Rice LW (1990) Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38: 46–48PubMedGoogle Scholar
  50. Gretz HF, Economos K, Husain A et al. (1996) The practice of surgical staging and its impact on adjuvant treatment recommendations in patientswith stage I endometrial carcinoma.Gynecol Oncol 61: 409–415Google Scholar
  51. Hall JB,Young RH, Nelson JH (1984) The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol 17: 32–40Google Scholar
  52. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma:a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93–108PubMedGoogle Scholar
  53. Homesley HD, Kadar N, Barrett RJ, Lentz SS (1992) Selective pelvic and peraortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol 167: 12251230Google Scholar
  54. Janicek MF, Rosenshein MB (1994) Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia.Gynecol Oncol 52:373378Google Scholar
  55. Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C, Oliver RTD (1996) Long-term follow-up of gonadotrophin-releasing hormone analogue treatment for recurrent endometrial cancer. Gynecol Oncol 63: 47–52PubMedGoogle Scholar
  56. Judd HI,Shamonki IM,Frumar AM, Lagasse ID (1982) Origin of serum estro- diol in postmenopausal women. Obstet Gynecol 59: 680–686Google Scholar
  57. Kadar N, Homesley HD, Malfetano JH (1992) Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 46: 145PubMedGoogle Scholar
  58. Kadar N, Malfetano JH, Homesley HD (1993) Steroid receptor concentrations in endometrial carcinoma:effect on survival in surgically staged patients. Gynecol Oncol 50: 281–286PubMedGoogle Scholar
  59. Kauppila A, Kujansuu E, Vihko R (1982) Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin, clinical correlates. Cancer 50: 2157–2162PubMedGoogle Scholar
  60. Kikuchi A, Sultana J, Okai T, Kobayashi K, Taketani Y (1997) Intrauterine sonography for preoperative assessment of cervical invasion in endometrial carcinoma. Gynecol Oncol 65: 415–420PubMedGoogle Scholar
  61. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W (1995) Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33PubMedGoogle Scholar
  62. Kleine W, Fuchs A, deGregorio G, Geyer H (1982) Ostrogen- and Progesteronrezeptoren beim Korpuskarzinom and ihre klinische Bedeutung. Geburtsh Frauenhk 42: 884–887Google Scholar
  63. Kucera H, Vavra N (1991) Ein Risiko-Score für das operierte Endometriumkarzinom and seine Bedeutung für die adjuvante Strahlentherapie. Geburtsh Frauenhk 51: 798–805Google Scholar
  64. Kucera H (1996) Ergebnisse and Nebenwirkungen der Postoperativen Strahlentherapie beim Korpuskarzinom. In: Ladner HA (Hrsg) Gynäkologische Radiologie. Springer, Berlin Heidelberg New York Tokyo, pp 26–34Google Scholar
  65. Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of„untreated” hyperplasia in 170 patients. Cancer 56: 403–412PubMedGoogle Scholar
  66. Kurman RJ, Norris HJ (1987) Endometrial carcinoma. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract, 3rd edn. Springer, Berlin Heidelberg New York Tokyo, pp 338–372Google Scholar
  67. Kurman RJ, Norris Hi (1982) Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well differentiated carcinoma. Cancer 49: 2547PubMedGoogle Scholar
  68. Ladner S (1997) Das Vaginalrezidiv beim Endometriumkarzinom. Ina ugural-Dissertation, FreiburgGoogle Scholar
  69. Larson DM, Johnson K, Olson KA (1992) Pelvic and paraaortic lymphadenectomy for surgical staging of endometrial cancer: Morbidity and mortality. Obstet Gynecol 79: 998–1001PubMedGoogle Scholar
  70. Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36: 189–191PubMedGoogle Scholar
  71. Lellé RJ, Morley GW, Peters WA (1994) The role of vaginal hysterectomy in the treatment of endometrial carcinoma. Int J Gynecol Cancer 4: 342–347PubMedGoogle Scholar
  72. Lesko SM, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Lewis JL Jr, Shapiro S (1985) Cigarette smoking and the risk of endometrial cancer. N Engl J Med 313: 593–596PubMedGoogle Scholar
  73. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh II, Wharton JT (1992) Uterine papillary serous carcinoma treated with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 46: 317321Google Scholar
  74. Lo SST, Cheng KL, Ng TY,Wong LC, Ngan HYS (1996) The prognostic significance of positive peritoneal cytology in endometrial cancer. Int J Gynecol Cancer 6: 473–476Google Scholar
  75. Lutz MH, Underwood PB Jr, Kreutner A Jr, Miller MC (1978) Endometrial carcinoma:a new method of classification of therapeutic and prognostic significance. Gynecol Oncol 6: 83–94PubMedGoogle Scholar
  76. Mack TM (1985) Estrogen replacement therapy in the etiology of endometrial Cancer.ln:Bolla M (ed) Endometrial cancers.5th Cancer Res.Workshop, Grenoble. Karger, Basel, pp 22–30Google Scholar
  77. Mangioni C, DePalo G,Marubini E, Del Vecchio M (1993) Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer 3: 373–384Google Scholar
  78. Mariani A, Sebo TJ, Katzmann JA, Keeney GL, Roche PC, LesnickTG, Podratz KC (2000) Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 182: 1535–1544Google Scholar
  79. Marziale P, Atlante G, Pozzi M, Diotallevi F, lacovelli A (1989) 426 cases of stage I endometrial carcinoma:a clinicopathological analysis.Gynecol Oncol 32: 278–281Google Scholar
  80. Meerpohl HG (1991) Systemic chemotherapy for advanced or recurrent endometrial cancer. In: Kleine W et al. (Hrsg) Therapie des Endometriumkarzinoms. Springer, Berlin Heidelberg New York Tokyo, pp 133141Google Scholar
  81. Milosevic ME, Dembo AJ,Thomas GM (1992)The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma. Int J Gynecol Cancer 2: 225–235Google Scholar
  82. Minckwitz G von, Kühn W, Kaufmann M, Feichter GE, Heep J, Schmid H, Bastert G (1994) Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer. Int J Gynecol Cancer 4: 250–256Google Scholar
  83. Minckwitz G von, Loibl S, Brunnert K et al., for the South West German Gynecologic Oncology Group (SWGGOG) (2002) Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlled, prospectively randomised trial.Euri Cancer 38: 2266–2272Google Scholar
  84. Morris PC, Anderson JR, Anderson B, Buller RE (1995) Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 56: 406–411PubMedGoogle Scholar
  85. Morrow CP, Bunda BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, Thigpen JT (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high risk endometrial carcinoma stage I and occult II:A Gynecologic Oncology Group study.Gynecol Oncol 36: 166–171Google Scholar
  86. Morrow CP, Bundy BN,Kurmann Ri,Creasman WT, Heller PB, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. A Gynecologic Oncology Group study. Gynecol Oncol 40: 55–65Google Scholar
  87. Moss WT, Brand WN, Battifora H (1979) Radiation oncology - rationale, technique, results, 5th edn. CV Mosby, St. Louis, p 492Google Scholar
  88. Nguyen C, Souhami L, Roman TN, Clark BG (1995) High-dose-rate brachytherapy as the primary treatment of medically inoperable stage I-II endometrial carcinoma. Gynecol Oncol 59: 370–375PubMedGoogle Scholar
  89. Nyholm HO, Nielsen AL, Norup P (1993) Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment.Comparison of clinical and histopathological characteristics. Gynecol Oncol 49: 229–235PubMedGoogle Scholar
  90. Persson I (1985) The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies. Acta Obstet Gynecol Scand Suppl 130: 59–66PubMedGoogle Scholar
  91. Pettersson F (1994) Annual report on the results of treatment in gynecol- ogical cancer, vol 22. Editorial Office, Radiumhemmet, StockholmGoogle Scholar
  92. Pfisterer J, Kommoss F, Sauerbrei W, Rendl I, Kiechle M, Kleine W, Pfleiderer A (1995) Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 58: 149–156PubMedGoogle Scholar
  93. Pfleiderer A (1991) Die Therapie des Endometriumkarzinoms. Geburtsh Frauenhk 51: 787–797Google Scholar
  94. Pfleiderer A (1996) Zur gynäkologischen Onkologie and operativen Gynäkologie im Alter.Gynäkologe 29: 770–774Google Scholar
  95. Pfleiderer A, Kleine W (1985) Risk factors of endometrial carcinoma. In: Bolla M (ed) Endometrial cancers.5th Cancer Res.Workshop,Grenoble 1985. Karger, Basel, pp 12–21Google Scholar
  96. Pierga JY, Dieras V, Paraiso D et al. (1996) Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin and 5–fluorouracil:A phase II study. Gynecol Oncol 60: 59–63PubMedGoogle Scholar
  97. Pike MC, Spicer DV (2000) Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 7: 73–83PubMedGoogle Scholar
  98. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT (1993) Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma. Gynecol Oncol 51: 383–389PubMedGoogle Scholar
  99. Reddoch JM, Burke TW, Morris M,Tornos C, Levenback C, Gershenson DM (1995) Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 59: 221–225Google Scholar
  100. Reich O, Winter R, Pickel H,Tamussino K, Haas J, Petru E (1996) Does the size of pelvic lymph nodes predict metastatic involvement in patients with endometrial cancer? Int J Gynecol Cancer 6: 445–447Google Scholar
  101. Robboy SJ, Bentley RC, Krigman H, Silverberg SG, Norris HJ, Zaino RJ (1994) Synoptic reports in gynecologic pathology. Int J Gynecol Pathol 13: 161–174PubMedGoogle Scholar
  102. Rosenberg P, Blom R, Hogberg T, Simonsen E (1993) Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma.Gynecol Oncol 51: 311–315Google Scholar
  103. Seelbach-Göbel B, Rempen A, Kristen P (1995) Transvaginaler Ultraschall am Endometrium in der Postmenopause. Geburtsh Frauenhk 54: 59–64Google Scholar
  104. Shelley DR, Dunaif A (1990) Polycystic ovary syndrome. Compr Ther 16: 26–34PubMedGoogle Scholar
  105. Shumsky AG, Brasher PMA, Stuart GCE, Nation JG (1997) Risk-specific follow-up for endometrial carcinoma patients. Gynecol Oncol 65: 379382Google Scholar
  106. Sood AK, Buller RE, Burger RA, Dawson JD, SoroskyJI, Berman M (1997) Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90: 441–447Google Scholar
  107. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW,Grendys EC (1996) A phase 11 GOG trial of ifosfamid and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 63: 25–27Google Scholar
  108. Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, Cohen 1(1997) Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 64: 386–391Google Scholar
  109. Thipgen JT, Blessing JA (1989) Progestin therapy for advanced or recurrent endometrial carcinoma: The GOG experience. Abst. Progestin action and progesteron receptors in breast cancer,April 6–7, Washington DC, NCI, AGGoogle Scholar
  110. Tsuda H, Kawabata M,Yamamoto K, Inoue T, Umesaki N (1997) Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies.Gynecol Oncol 65: 383–386Google Scholar
  111. Umpierre SA, BurkeTW,Tornos C, Ordonez N, Levenback C, Morris M (1994) Immunocytochemical analysis of uterine papillary carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 13: 127130Google Scholar
  112. Vergote I, Kjörstad K, Abeler V, Kolstad P (1989) A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64: 1011–1016PubMedGoogle Scholar
  113. Vuento MH, Stenman UH, Pirhonen JP, Mäkinen JI, Laippala PJ, Salmi TA (1997) Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol 64: 141–146PubMedGoogle Scholar
  114. Watson P, Lynch IIT (1993) Extracolonic cance in hereditary nonpolyposis colorectal cancer. Cancer 71: 677–685PubMedGoogle Scholar
  115. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD Jr, O’Brien PC, Naessens JM (1990) Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 162: 418–423Google Scholar
  116. Yokoyama Y, Maruyama H, Sato S, Saito Y (1997) Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 64: 411–417PubMedGoogle Scholar
  117. Zablow A, Adams M, Gregori C, Breen JL, Sanfilippo U (1994) Stage II adenocarcinoma of the endometrium treated by two standard regimens of combined preoperative irradiation and surgery. Int J Gynecol Cancer 4: 265–271PubMedGoogle Scholar
  118. Zheng W,Cao P,Zheng M, Kramer EE,Godwin TA (1996) p53 overexpression and bc1–2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61: 167–174Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • G. von Minckwitz
  • A. Pfleiderer
  • M. Kaufmann

There are no affiliations available

Personalised recommendations